{"id":78741,"date":"2026-09-04T15:44:06","date_gmt":"2026-09-04T07:44:06","guid":{"rendered":"https:\/\/flcube.com\/?p=78741"},"modified":"2026-09-04T15:44:07","modified_gmt":"2026-09-04T07:44:07","slug":"takeda-and-belief-biomed-end-xinjiuning-commercialization-partnership-belief-biomed-to-advance-gene-therapy-independently","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=78741","title":{"rendered":"Takeda and Belief BioMed End Xinjiuning Commercialization Partnership; Belief BioMed to Advance Gene Therapy Independently"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Takeda Pharmaceutical Company Limited (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/4502:TYO\">TYO: 4502<\/a>; <a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/TAK:NYSE\">NYSE: TAK<\/a>) China<\/strong> and <strong>Belief BioMed Inc.<\/strong> issued a joint statement announcing the official termination of their commercialization collaboration for <strong>dalnacogene ponparvovec injection (trade name: Xinjiuning)<\/strong>, a <strong>hemophilia B gene therapy<\/strong>, effective <strong>August 2<\/strong>. Despite being <strong>China\u2019s first approved domestic AAV-based gene therapy<\/strong>, the product has not recorded a single prescription to date, and <strong>Belief BioMed<\/strong> now plans to independently advance its commercialization while maintaining medical support for relevant patients.<\/p>\n\n\n\n<h2 id=\"h-transaction-amp-regulatory-background\" class=\"wp-block-heading\">Transaction &amp; Regulatory Background<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td>Parties<\/td><td><strong>Takeda China<\/strong> and <strong>Belief BioMed Inc.<\/strong><\/td><\/tr><tr><td>Action<\/td><td>Termination of commercialization collaboration for <strong>Xinjiuning<\/strong> (dalnacogene ponparvovec)<\/td><\/tr><tr><td>Effective Date<\/td><td>02 Aug 2026<\/td><\/tr><tr><td>Original Agreement<\/td><td>Oct 2023 \u2013 Takeda China obtained commercialization rights for mainland China, Hong Kong and Macau<\/td><\/tr><tr><td>Product Approval<\/td><td>Apr 2025, NMPA<\/td><\/tr><tr><td>Indication<\/td><td>Adult patients with moderate to severe <strong>hemophilia B<\/strong> (congenital coagulation factor IX deficiency)<\/td><\/tr><tr><td>Next Steps<\/td><td><strong>Belief BioMed<\/strong> to independently advance commercialization and patient medical support<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-commercial-history\" class=\"wp-block-heading\">Drug Profile &amp; Commercial History<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> <strong>dalnacogene ponparvovec (Xinjiuning)<\/strong>, an AAV-based gene therapy delivering factor IX for <strong>hemophilia B<\/strong><\/li>\n\n\n\n<li><strong>Milestone Status:<\/strong> First approved domestic AAV-based gene therapy in China (Apr 2025)<\/li>\n\n\n\n<li><strong>Initial Pricing:<\/strong> RMB 93,000 per vial, with total patient out-of-pocket costs reaching several million yuan depending on body weight<\/li>\n\n\n\n<li><strong>Access Measures:<\/strong> Patient assistance programs, inclusion of city-level supplemental health insurance (<strong>Huiminbao<\/strong>) support, and subsequent price reductions were implemented<\/li>\n\n\n\n<li><strong>Commercial Outcome:<\/strong> Despite these measures, <strong>Xinjiuning<\/strong> has yet to record a single prescription to date<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-commentary\" class=\"wp-block-heading\">Strategic Commentary<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Dr. Xiao Xiao<\/strong>, co-founder, chairman and chief scientist of <strong>Belief BioMed<\/strong>, described the termination as a mutual business decision driven by strategic refocusing at both parties<\/li>\n\n\n\n<li>The termination does not signal a pause in <strong>Xinjiuning\u2019s<\/strong> commercialization; <strong>Belief BioMed<\/strong> will independently take over the product\u2019s market launch and ongoing medical support arrangements for relevant patients<\/li>\n\n\n\n<li><strong>Takeda<\/strong> exits a collaboration that had paired its global rare-disease commercial expertise with a first-in-class domestic gene therapy<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Affordability challenge:<\/strong> The case underscores the structural barriers facing high-cost, weight-based gene therapies in China, where multi-million-yuan out-of-pocket burdens persist even after assistance programs and <strong>Huiminbao<\/strong> coverage<\/li>\n\n\n\n<li><strong>Commercial model reset:<\/strong> Gene therapy launch strategies in China are being recalibrated toward sustainable reimbursement pathways rather than reliance on patient assistance alone<\/li>\n\n\n\n<li><strong>Belief BioMed\u2019s burden and upside:<\/strong> Full commercial ownership concentrates both execution risk and potential reward on the company, whose next steps will test the viability of independent rare-disease launches<\/li>\n\n\n\n<li><strong>Sector signal:<\/strong> The split adds to growing evidence that global pharma\u2013biotech partnerships in China are being reassessed where commercial traction lags<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements:<\/strong> This brief is for informational purposes only and does not constitute investment advice or an offer to buy or sell any security. Statements regarding commercialization plans, pricing dynamics and market potential are forward-looking and subject to risks and uncertainties, including reimbursement policy changes, competitive developments and execution outcomes. Actual results may differ materially. Readers should conduct their own due diligence before making investment decisions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) China and Belief BioMed Inc. issued a&#8230;<\/p>\n","protected":false},"author":1,"featured_media":78743,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10,11,4908],"tags":[465,66,874,345,1141],"class_list":["post-78741","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","category-drug","category-pic","tag-belief-biomed","tag-gene-therapy","tag-nyse-tak","tag-takeda","tag-tyo-4502"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Takeda and Belief BioMed End Xinjiuning Commercialization Partnership; Belief BioMed to Advance Gene Therapy Independently - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) China and Belief BioMed Inc. issued a joint statement announcing the official termination of their commercialization collaboration for dalnacogene ponparvovec injection (trade name: Xinjiuning), a hemophilia B gene therapy, effective August 2. Despite being China\u2019s first approved domestic AAV-based gene therapy, the product has not recorded a single prescription to date, and Belief BioMed now plans to independently advance its commercialization while maintaining medical support for relevant patients.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=78741\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Takeda and Belief BioMed End Xinjiuning Commercialization Partnership; Belief BioMed to Advance Gene Therapy Independently\" \/>\n<meta property=\"og:description\" content=\"Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) China and Belief BioMed Inc. issued a joint statement announcing the official termination of their commercialization collaboration for dalnacogene ponparvovec injection (trade name: Xinjiuning), a hemophilia B gene therapy, effective August 2. Despite being China\u2019s first approved domestic AAV-based gene therapy, the product has not recorded a single prescription to date, and Belief BioMed now plans to independently advance its commercialization while maintaining medical support for relevant patients.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=78741\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-04T07:44:06+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-04T07:44:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/0401.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78741#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78741\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Takeda and Belief BioMed End Xinjiuning Commercialization Partnership; Belief BioMed to Advance Gene Therapy Independently\",\"datePublished\":\"2026-09-04T07:44:06+00:00\",\"dateModified\":\"2026-09-04T07:44:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78741\"},\"wordCount\":495,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78741#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/0401.webp\",\"keywords\":[\"Belief BioMed\",\"Gene therapy\",\"NYSE: TAK\",\"Takeda\",\"TYO: 4502\"],\"articleSection\":[\"Company\",\"Deals\",\"Drug\",\"PIC\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=78741#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78741\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=78741\",\"name\":\"Takeda and Belief BioMed End Xinjiuning Commercialization Partnership; Belief BioMed to Advance Gene Therapy Independently - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78741#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78741#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/0401.webp\",\"datePublished\":\"2026-09-04T07:44:06+00:00\",\"dateModified\":\"2026-09-04T07:44:07+00:00\",\"description\":\"Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) China and Belief BioMed Inc. issued a joint statement announcing the official termination of their commercialization collaboration for dalnacogene ponparvovec injection (trade name: Xinjiuning), a hemophilia B gene therapy, effective August 2. Despite being China\u2019s first approved domestic AAV-based gene therapy, the product has not recorded a single prescription to date, and Belief BioMed now plans to independently advance its commercialization while maintaining medical support for relevant patients.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78741#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=78741\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78741#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/0401.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/0401.webp\",\"width\":1080,\"height\":608,\"caption\":\"Takeda and Belief BioMed End Xinjiuning Commercialization Partnership; Belief BioMed to Advance Gene Therapy Independently\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78741#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Takeda and Belief BioMed End Xinjiuning Commercialization Partnership; Belief BioMed to Advance Gene Therapy Independently\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Takeda and Belief BioMed End Xinjiuning Commercialization Partnership; Belief BioMed to Advance Gene Therapy Independently - Insight, China&#039;s Pharmaceutical Industry","description":"Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) China and Belief BioMed Inc. issued a joint statement announcing the official termination of their commercialization collaboration for dalnacogene ponparvovec injection (trade name: Xinjiuning), a hemophilia B gene therapy, effective August 2. Despite being China\u2019s first approved domestic AAV-based gene therapy, the product has not recorded a single prescription to date, and Belief BioMed now plans to independently advance its commercialization while maintaining medical support for relevant patients.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=78741","og_locale":"en_US","og_type":"article","og_title":"Takeda and Belief BioMed End Xinjiuning Commercialization Partnership; Belief BioMed to Advance Gene Therapy Independently","og_description":"Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) China and Belief BioMed Inc. issued a joint statement announcing the official termination of their commercialization collaboration for dalnacogene ponparvovec injection (trade name: Xinjiuning), a hemophilia B gene therapy, effective August 2. Despite being China\u2019s first approved domestic AAV-based gene therapy, the product has not recorded a single prescription to date, and Belief BioMed now plans to independently advance its commercialization while maintaining medical support for relevant patients.","og_url":"https:\/\/flcube.com\/?p=78741","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-09-04T07:44:06+00:00","article_modified_time":"2026-09-04T07:44:07+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/0401.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=78741#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=78741"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Takeda and Belief BioMed End Xinjiuning Commercialization Partnership; Belief BioMed to Advance Gene Therapy Independently","datePublished":"2026-09-04T07:44:06+00:00","dateModified":"2026-09-04T07:44:07+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=78741"},"wordCount":495,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=78741#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/0401.webp","keywords":["Belief BioMed","Gene therapy","NYSE: TAK","Takeda","TYO: 4502"],"articleSection":["Company","Deals","Drug","PIC"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=78741#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=78741","url":"https:\/\/flcube.com\/?p=78741","name":"Takeda and Belief BioMed End Xinjiuning Commercialization Partnership; Belief BioMed to Advance Gene Therapy Independently - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=78741#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=78741#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/0401.webp","datePublished":"2026-09-04T07:44:06+00:00","dateModified":"2026-09-04T07:44:07+00:00","description":"Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) China and Belief BioMed Inc. issued a joint statement announcing the official termination of their commercialization collaboration for dalnacogene ponparvovec injection (trade name: Xinjiuning), a hemophilia B gene therapy, effective August 2. Despite being China\u2019s first approved domestic AAV-based gene therapy, the product has not recorded a single prescription to date, and Belief BioMed now plans to independently advance its commercialization while maintaining medical support for relevant patients.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=78741#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=78741"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=78741#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/0401.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/0401.webp","width":1080,"height":608,"caption":"Takeda and Belief BioMed End Xinjiuning Commercialization Partnership; Belief BioMed to Advance Gene Therapy Independently"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=78741#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Takeda and Belief BioMed End Xinjiuning Commercialization Partnership; Belief BioMed to Advance Gene Therapy Independently"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/0401.webp","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/78741","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=78741"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/78741\/revisions"}],"predecessor-version":[{"id":78745,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/78741\/revisions\/78745"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/78743"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=78741"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=78741"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=78741"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}